Etelcalcetide (Parsabiv®)

Assessment Status Rapid review complete
Drug Etelcalcitide
Brand Parsabiv®
Indication For the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.
Assessment Process
Rapid review commissioned 14/06/2017
Rapid review completed 01/09/2017
Rapid review outcome Full pharmacoeconomic assessment recommended at the submitted price

The HSE has approved reimbursement following confidential price negotiations; April 2018.